The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients with dry eye disease
MENLO PARK, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that a new study titled, Impact of TearCare on Reading Speed in Patients with Dry Eye Disease, has been published in the peer-reviewed journal Clinical Ophthalmology.
Key study findings reported in the study manuscript include:
“A large portion of the patients I see in my practice experience significant issues from their dry eye disease. The disease can impact their quality of life and when it goes untreated patients can have reduced visual function,” said Preeya K. Gupta, MD, senior author and Director of Triangle Eye Consultants. “We are very pleased that this study demonstrated how a single in-office intervention with TearCare addressed the visual dysfunction associated with dry eye disease.”
This prospective single-center study evaluated the impact of TearCare treatment on clinical, vision-related quality of life, and functional visual outcome metrics in patients with meibomian gland disease (“MGD”) associated DED. The findings suggest patients who underwent a TearCare treatment exhibited improvements in vision-related quality of life and improved reading speeds after a single treatment. The study suggests that this interventional dry eye treatment should be considered and utilized to reduce the disease burden of MGD associated DED.
Authors and affiliations:
Yilin Feng MD1, Nandini Venkateswaran MD1, Amanda Steele OD2, Eric D Rosenberg DO, MScEng3, Preeya K. Gupta MD2,4
Paper Reference:
Feng Y, Venkateswaran N, Steele A, Rosenberg ED, Gupta PK. Impact of TearCare on Reading Speed in Patients with Dry Eye Disease. Clin Ophthalmol. 2024;18:2873-2878
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. Glaucoma is the world’s leading cause of irreversible blindness, and the Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE-marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”), when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo, and TearCare are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2024 Sight Sciences. All rights reserved.
Media contact:
pr@SightSciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。